Search Within

Genitourinary Oncology Service

  1. "Steven Larson"
Formats
  1. Journal Article (79)
  2. Meeting Abstract (69)
  3. Review (2)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (151)
  2. GSK Faculty (151)
  3. Molecular Imaging and Therapy Service (151)
  4. Molecular Pharmacology and Chemistry Program Faculty (151)
  5. Radiology, Department of (151)
  6. Sloan Kettering Institute Faculty (151)

More Groups

People
  1. Steven Larson (151)
  2. Howard Scher (110)
  3. Michael Morris (93)
  4. Neeta Pandit-Taskar (35)
  5. John Humm (31)
  6. Josef Fox (29)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (2)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (46)
  2. Journal of Nuclear Medicine (32)
  3. Clinical Cancer Research (18)
  4. Cancer Research (7)
  5. Cancer (3)
  6. European Journal of Nuclear Medicine and Molecular Imaging (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (47)
  2. Society of Nuclear Medicine (32)
  3. American Association for Cancer Research (29)
  4. Springer (9)
  5. Nature Publishing Group (6)
  6. Elsevier Inc. (4)

More Publishers

Results (151)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Automated bone scan index to optimize prostate cancer working group radiographic progression criteria for men with metastatic castration-resistant prostate cancer
    Journal Article

    Anand, A.; Heller, G.; Fox, J.; Danila, D. C.; Bjartell, A.; Edenbrandt, L.; Larson, S. M.; Scher, H. I.; Morris, M. J.
    Clinical Genitourinary Cancer (2022)

    Fulltext@MSK | Save
  • Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: A single-center retrospective cohort study
    Journal Article

    Wibmer, A. G.; Morris, M. J.; Gonen, M.; Zheng, J.; Hricak, H.; Larson, S.; Scher, H. I.; Vargas, H. A.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • PSA-targeted alpha-, beta-, and positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
    Journal Article

    Veach, D. R.; Storey, C. M.; Lückerath, K.; Braun, K.; von Bodman, C.; Lamminmäki, U.; Kalidindi, T.; Strand, S. E.; Strand, J.; Altai, M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • First-in-humans trial of dasatinib-derivative tracer for tumor kinase-targeted PET
    Journal Article

    Krebs, S.; Veach, D. R.; Carter, L. M.; Grkovski, M.; Fornier, M.; Mauro, M. J.; Voss, M. H.; Danila, D. C.; Burnazi, E.; Null, M.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer
    Journal Article

    Wise, D. R.; Schneider, J. A.; Armenia, J.; Febles, V. A.; McLaughlin, B.; Brennan, R.; Thoren, K. L.; Abida, W.; Sfanos, K. S.; De Marzo, A. M.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save